InMed Pharmaceuticals (INM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InMed Pharmaceuticals announced the results of their 2024 Annual General Meeting, where shareholders approved the election of four directors and the appointment of CBIZ LLP as their auditors for the coming year. However, the election of Ms. Janet Grove was withheld, prompting her resignation offer, which is under consideration. The company is focused on developing drug candidates for diseases with high unmet needs.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.